Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study

BACKGROUND: Despite the wide-spread use of immune checkpoint inhibitors (ICIs) in cancer chemotherapy, reports on patients developing acquired resistance (AR) to ICI therapy are scarce. Therefore, we first investigated the characteristics associated with shorter durable responses of ICI treatment an...

Descripción completa

Detalles Bibliográficos
Autores principales: Hosoya, Kazutaka, Fujimoto, Daichi, Morimoto, Takeshi, Kumagai, Toru, Tamiya, Akihiro, Taniguchi, Yoshihiko, Yokoyama, Toshihide, Ishida, Tadashi, Matsumoto, Hirotaka, Hirano, Katsuya, Kominami, Ryota, Tomii, Keisuke, Suzuki, Hidekazu, Hirashima, Tomonori, Tanaka, Satoshi, Uchida, Junji, Morita, Mitsunori, Kanazu, Masaki, Mori, Masahide, Nagata, Kenji, Fukuda, Ikue, Tamiya, Motohiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017679/
https://www.ncbi.nlm.nih.gov/pubmed/33794809
http://dx.doi.org/10.1186/s12885-021-08048-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017679/
https://www.ncbi.nlm.nih.gov/pubmed/33794809
http://dx.doi.org/10.1186/s12885-021-08048-4

Ejemplares similares